



Celsion Corporation  
Investor Relations Department  
997 Lenox Drive  
Suite 100  
Lawrenceville, NJ 08648  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: CLSN**

Last Trade:	2.62
Trade Time:	12:52 PM ET Jan 17, 2018
Change:	-0.03 <span style="color:red">▼</span> (-1.132%)
Day Range	2.60 - 2.69
52-Week Range	1.24 - 7.70
Volume	119,215

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

### Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the side-effects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heat-sensitive liposomal nanoparticle licensed from Duke Universit... [\(more\)](#)

### Stock Performance



### Press Releases [\[ View all \]](#)

- Jan 4, 2018*  
[Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer](#)
- Nov 20, 2017*  
[Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, "TARDOX Study Protocol" in the Journal of Therapeutic Ultrasound](#)
- Nov 14, 2017*  
[Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update](#)
- Nov 13, 2017*  
[CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer](#)
- Nov 13, 2017*  
[Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer](#)

### Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 24, 2017*  
[Annual Report \(10-K\)](#)
- Apr 4, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 14, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 14, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 12, 2017*  
[Quarterly Report \(10-Q\)](#)